



# pan-Canadian Oncology Drug Review Patient Advocacy Group Feedback on a pCODR Expert Review Committee Initial Recommendation

## Bevacizumab (Avastin) for Cervical Cancer

## Ovarian Cancer Canada

March 23, 2015

## 1 Feedback on pERC Initial Recommendation

Name of the drug and indication(s): Bevacizumab (Avastin) for cervical cancer

Name of registered patient advocacy group: Ovarian Cancer Canada

### 1.1 Comments on the Initial Recommendation

- a) Please indicate if the patient advocacy group agrees or disagrees with the initial recommendation:

agrees                       agrees in part                       disagree

*Please explain why the patient advocacy group agrees, agrees in part or disagrees with the initial recommendation.*

We agree that Bevacizumab (Avastin) should be funded for patients with carcinoma of the cervix. We don't agree that this funding should be conditional upon cost-effectiveness being improved to an acceptable level. We believe this drug should be funded regardless.

- b) Notwithstanding the feedback provided in part a) above, please indicate if the patient advocacy group would support this initial recommendation proceeding to final pERC recommendation ("early conversion"), which would occur within 2(two) business days of the end of the consultation period.

Support conversion to final recommendation.

Do not support conversion to final recommendation.

Recommendation does not require reconsideration by pERC.

Recommendation should be reconsidered by pERC.

- c) Please provide feedback on the initial recommendation. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page Number	Section Title	Paragraph, Line Number	Comments and Suggested Changes to Improve Clarity
4		2	The cost effectiveness section was not clear to us. We didn't understand what this meant. Wondered if this meant it would not be approved unless cost of drug was lowered.
7	Cost-effectiveness		Similar to comment above.

### 1.2 Comments Related to Patient Advocacy Group Input

Please provide feedback on any issues not adequately addressed in the initial recommendation based on patient advocacy group input provided at the outset of the review on outcomes or issues important to patients that were identified in the submitted patient input. Please note

that new evidence will be not considered during this part of the review process, however, it may be eligible for a Resubmission. If you are unclear as to whether the information you are providing is eligible for a Resubmission, please contact the pCODR Secretariat.

Examples of issues to consider include: what are the impacts of the condition on patients’ daily living? Are the needs of patients being met by existing therapies? Are there unmet needs? Will the agents included in this recommendation affect the lives of patients? Do they have any disadvantages? Stakeholders may also consider other factors not listed here.

Page Number	Section Title	Paragraph, Line Number	Comments related to initial patient advocacy group input

**1.3 Additional Comments About the Initial Recommendation Document**

Please provide any additional comments:

Page Number	Section Title	Paragraph, Line Number	Additional Comments